FDA authorizes more J&J vaccines made at Emergent plant

The FDA has authorized another batch of Johnson & Johnson COVID-19 vaccines made at Emergent BioSolutions' Baltimore plant to be distributed for use, the agency said June 15.

A total of three batches from the facility have been approved, totaling about 25 million doses of vaccine, a U.S. official told The Wall Street Journal.